High Lp(a): what it means and what to do next
Lipoprotein(a) is a genetically determined cholesterol particle that raises the risk of heart attack, stroke, peripheral artery disease and aortic valve stenosis — even when standard cholesterol looks normal.
Read the clinical review →Lp(a) is a cholesterol particle most people have never heard of — yet in roughly one in five adults it raises the lifetime risk of heart attack, stroke, peripheral artery disease and aortic valve narrowing. Because it is set largely by your genes, no amount of diet or exercise will lower it. The good news: a single blood test tells you your level for life, and knowing it changes how aggressively you should manage everything else.
What is Lp(a)?
Lipoprotein(a) — often pronounced “Lp little a” — is a cholesterol particle very similar to LDL (“bad cholesterol”), but with an extra protein called apolipoprotein(a) attached. That tail makes the particle stickier inside artery walls and more likely to drive plaque build-up. It also has a unique role in calcifying the aortic valve, which standard cholesterol particles do not.
Unlike LDL cholesterol, your Lp(a) level is overwhelmingly written into your DNA. Diet, exercise, weight loss and the cholesterol medicines most people take (statins, ezetimibe) make almost no difference to the level itself. About one in five adults has a level high enough to add meaningful cardiovascular risk — and most never know.
| Standard cholesterol (LDL) | Lipoprotein(a) — Lp(a) | |
|---|---|---|
| What it is | The “bad cholesterol” particle | An LDL-like particle with an extra sticky tail attached |
| What sets your level | Diet, lifestyle, weight, genetics | About 90% genetic — set at birth |
| Effect of lifestyle | Significant | Minimal |
| Routine cholesterol panel | Yes | No — needs a separate request |
| How often to check | Per usual care | Once in a lifetime is usually enough |
| Drives plaque in arteries | Yes | Yes — and more strongly per particle |
| Drives valve calcification | Indirectly | Yes — directly |
| Available treatments | Statins, ezetimibe, PCSK9 inhibitors, bempedoic acid | None approved yet — targeted therapies in late-stage trials |
Why does it matter?
Elevated Lp(a) is independently linked to four cardiovascular conditions. They often appear earlier or more aggressively than standard risk factors alone would predict.
Heart attack
Lp(a) drives plaque build-up in the coronary arteries on top of standard cholesterol — meaning a heart attack can occur even when LDL is well-controlled.
Stroke
Particularly ischaemic stroke — where plaque or a clot blocks blood flow to part of the brain. Lp(a) is associated with both atherosclerotic and embolic mechanisms.
Aortic valve narrowing
Lp(a) is the only cholesterol particle clearly linked to calcific aortic stenosis — the most common reason older adults need a valve replacement.
Peripheral artery disease
Narrowing of the leg arteries, which can cause leg pain on walking, slow wound healing and threaten limb circulation in advanced cases.
Who should be tested?
Major guidelines — including the National Lipid Association and the 2026 ACC/AHA dyslipidemia guideline — now recommend that every adult have their Lp(a) measured at least once. Because levels are genetically set, a single test gives a lifetime answer. Testing is especially important if any of the following apply:
Premature heart disease in the family
Heart attack, stroke, stent or bypass before age 55 in a male relative or 65 in a female relative.
Unexplained heart attack or stent
A previous cardiac event without an obvious explanation — particularly when standard cholesterol seemed under control.
Suspected familial hypercholesterolaemia
Very high cholesterol with a family pattern. Use the FH calculator to assess.
Cholesterol that won’t come down
High cholesterol that remains elevated despite appropriate medical therapy.
Intermediate risk on a calculator
Use the PREVENT calculator: Lp(a) helps reclassify borderline risk in either direction.
Aortic valve narrowing on echo
Calcific aortic stenosis — especially when it appears at a younger age than expected.
Your result on the Lp(a) risk scale
Lp(a) risk increases on a continuum — there is no single number that flips from “safe” to “dangerous.” The four bands below are a useful guide for what your level means and how aggressively to act.
A note on units. Australian labs report Lp(a) in nmol/L. International labs sometimes use mg/dL. There is no reliable conversion between the two because the apolipoprotein(a) molecule varies in size between people — use whichever your lab provides.
What to do if your Lp(a) is high
There is no approved medication that lowers Lp(a) directly — yet. Several are in late-stage trials (see below). But knowing your Lp(a) is high gives you something more important: a clear reason to be more aggressive with the things you can control.
Lower LDL cholesterol harder
Lp(a) adds risk on top of LDL. Hitting tighter LDL targets is one of the most effective ways to reduce overall risk. Discuss with your doctor whether your current therapy is intensive enough.
Take other risk factors seriously
Blood pressure, diabetes, smoking, weight and physical activity all matter more when Lp(a) is elevated. Each additional factor compounds the risk.
Get a coronary calcium score
A CAC score shows whether plaque has actually developed, helping decide how aggressively to treat. Reassuring if zero, action-prompting if not.
Test your family
Lp(a) is inherited. First-degree relatives — parents, siblings, children — should know their level. A single blood test is all that’s needed.
Consider an ApoB test
ApoB counts every atherogenic particle in your blood. It can reveal hidden risk when LDL alone underestimates the picture.
Don’t repeat the test
Because Lp(a) is genetic, levels rarely change. You don’t need another Lp(a) test unless there’s a specific clinical reason.
How to interpret your Lp(a) in context
A single Lp(a) number does not tell the whole story. The real impact depends on your age, sex, blood pressure, cholesterol, diabetes status, kidney function and whether plaque has already developed. Modern preventive cardiology uses three additional tools to build the complete picture:
PREVENT calculator
The 2024 American Heart Association tool estimating 10- and 30-year cardiovascular risk, including kidney and metabolic factors. Establishes your baseline.
Calculate my risk ImagingCoronary calcium score
A non-invasive CT scan that measures actual calcium in your coronary arteries — showing whether plaque has developed. Powerful for reclassifying borderline risk.
CAC calculator Lipid measurementApoB
A more complete measure of atherogenic particle burden than LDL alone — useful when standard cholesterol underestimates risk.
ApoB explainerPutting these pieces together — Lp(a), PREVENT, calcium score, ApoB — gives a much clearer picture than any single test alone. That is the kind of assessment performed in a preventive cardiology review.
The hype: targeted Lp(a) therapies coming soon
For decades, knowing about Lp(a) was useful but frustrating — there was nothing to do about the level itself. That is about to change. Five drugs are in clinical trials that lower Lp(a) by 70–95%, either by silencing the gene that makes apolipoprotein(a) or by blocking the Lp(a) particle from being assembled. The first cardiovascular outcome data is expected in the first half of 2026, with further readouts through 2027 and beyond.
| Drug | Trial | Type & dosing | Lp(a) reduction | Status & expected readout |
|---|---|---|---|---|
| Pelacarsen | Lp(a)HORIZON | Antisense oligonucleotide Monthly subcutaneous injection |
~80% | Phase 3 — first results expected in 1H 2026. The first cardiovascular outcomes trial of any Lp(a)-lowering drug. |
| Olpasiran | OCEAN(a)-Outcomes | Small interfering RNA (siRNA) Every 12 weeks subcutaneous |
> 95% | Phase 3 — ~7,300 patients enrolled, completion expected late 2026. |
| Lepodisiran | ACCLAIM-Lp(a) | Small interfering RNA (siRNA) Long-acting subcutaneous |
~94% | Phase 3 — ongoing, with phase 2 ALPACA data published in 2025. |
| Zerlasiran | ALPACAR-360 | Small interfering RNA (siRNA) Every 16–24 weeks subcutaneous |
~86% | Phase 2 complete; Phase 3 in planning. |
| Muvalaplin | KRAKEN | Oral small molecule (Lp(a) assembly inhibitor) Once daily tablet |
~70–86% | Phase 2 complete; Phase 3 in planning. The only oral agent in development. |
A separate question — does Lp(a) lowering also slow valve disease? A second pelacarsen trial, Lp(a)FRONTIERS CAVS, is testing whether lowering Lp(a) slows the progression of calcific aortic valve stenosis. Both questions matter, because Lp(a) drives both arterial and valve disease through partly independent pathways.
What does this mean for you? If you have very high Lp(a), the next two to three years will fundamentally change what we can offer. For now, the priority is to know your level, optimise everything else, and stay engaged with your doctor as new therapies become available.
When to see a cardiologist
An elevated Lp(a) is a useful prompt to step back and look at the whole picture — particularly when other risk factors are present or the cholesterol story doesn’t quite add up.
Your Lp(a) is elevated and any of these apply
- Strong family history of heart disease or stroke
- High or difficult-to-control cholesterol
- A coronary calcium score that needs interpretation
- Uncertainty about starting or intensifying statin therapy
- Known or suspected familial hypercholesterolaemia
- A previous cardiac event without a clear explanation
- Aortic valve narrowing on a recent echocardiogram
Your full cardiovascular picture in one plan
- Full lipid panel and Lp(a) interpretation
- Cardiovascular risk assessment (PREVENT, family history)
- Coronary calcium score and imaging review
- Personalised LDL and blood pressure targets
- Family screening recommendations
- Clear follow-up plan
- Lp(a) is largely genetic — you cannot diet, exercise or lose weight to lower it.
- One blood test in your lifetime is usually enough — levels stay stable.
- High Lp(a) means more aggressive management of the risk factors you can control — especially LDL cholesterol.
- Targeted Lp(a)-lowering therapies are in late-stage trials, with the first cardiovascular outcomes results expected from 2026.
- Family screening is recommended — first-degree relatives should know their level.
Frequently asked questions
Should everyone be tested for Lp(a)?
Major guidelines now recommend that every adult have their Lp(a) measured at least once in their lifetime. Because Lp(a) is largely genetic and does not change much over time, a single test gives a lifetime answer. Testing is especially important if you have a family history of early heart disease, known high cholesterol, or are making decisions about statin therapy.
Can diet or exercise lower Lp(a)?
No. Unlike LDL cholesterol or triglycerides, Lp(a) levels are determined almost entirely by genetics. Diet, exercise and weight loss have minimal effect on Lp(a). That is why management focuses on reducing the other risk factors you can control — particularly LDL cholesterol, blood pressure and smoking.
Are there treatments specifically for Lp(a)?
Not yet approved — but five targeted therapies are in clinical trials. These include injectable treatments (pelacarsen, olpasiran, lepodisiran, zerlasiran) and the oral agent muvalaplin, which have shown reductions in Lp(a) of 70–95% in earlier-phase studies. The first major cardiovascular outcomes trial (Lp(a)HORIZON, pelacarsen) is expected to read out in the first half of 2026 and will determine whether lowering Lp(a) directly reduces heart attacks and strokes. Read more in our comprehensive Lp(a) review.
Should my family be tested if my Lp(a) is high?
Yes. Because Lp(a) is inherited, first-degree relatives — parents, siblings, children — of someone with elevated Lp(a) have a higher probability of also having high levels. A single blood test for each family member can clarify their risk. If you also have a family pattern of high cholesterol, the FH calculator can help determine whether formal assessment for familial hypercholesterolaemia is warranted.
Will my GP order an Lp(a) test?
Yes, a GP can order Lp(a). It is a simple blood test, often added on to a routine cholesterol panel. In Australia, Lp(a) is not currently covered by Medicare for routine screening, so there may be a small out-of-pocket cost (typically modest). If your GP is unsure, ask for it specifically — current guidelines support measuring it once.
I’m fit, slim and my cholesterol is normal — do I still need this test?
Yes. Lp(a) is independent of LDL cholesterol, weight, fitness and lifestyle. Athletes, vegetarians and people with otherwise excellent cholesterol can still have very high Lp(a). The only way to know is a blood test. Lp(a) is one of the more common reasons for an unexplained heart attack in someone who appears to have done everything right.
Useful next steps
Estimate your overall risk — PREVENT
The guideline-recommended tool for 10- and 30-year cardiovascular risk.
Open calculator ImagingCoronary calcium risk calculator
Useful when your risk is borderline or you want to reclassify up or down.
Open calculator Inherited cholesterolFH calculator
Inherited high cholesterol often coexists with high Lp(a).
Open calculator Lipid scienceApoB explainer
ApoB counts total atherogenic particles — helpful when LDL underestimates risk.
Read more Clinical detailFull Lp(a) clinical review
In-depth coverage of genetics, pathophysiology, emerging therapies and trial updates.
Read more Guidelines2026 ACC/AHA dyslipidemia guideline
How Lp(a) fits into the latest framework alongside PREVENT, CAC and ApoB.
Read summaryPreventive cardiology review
Particularly relevant if you have high Lp(a), a family history of premature heart disease, or a coronary calcium score that needs interpretation. We bring your Lp(a), lipid profile, risk scores and imaging into a single clear plan.
Book an Appointment